As you are aware, Eli Lilly has taken the bold step of limiting all of their products (with the exception of some insulins) from being dispensed at 340B contract pharmacies. This action is unprecedented, and we believe violates the spirit of the 340B program. As such, we are working with various industry stakeholders to evaluate what options you may, and what actions we may take on your behalf as your 340B TPA.
In the meantime, we are compiling a 340B savings impact analysis for your covered entity should this practice be allowed to continue. We will be sending this impact analysis in the coming days to help you evaluate the best way to respond to this reduction in eligible 340B savings.
Eli Lilly’s latest action comes upon the heels of similar recent activity taken by other manufacturers including Merck, Sanofi, AstraZeneca and Novartis. For those products manufacturers are limiting distribution for 340B pricing, CaptureRx will establish blocks in our system the day of an announcement or within 48 hours. The most recent block due to the Eli Lilly limitation referenced above will be complete by EOD Saturday, September 5.
We recommend several steps that you can take right now in response to manufacturers’ recent actions.
- CaptureRx advises you seek out and obtain guidance from a legal firm or your counsel, your buying and networking associations and congressperson to discuss the recent manufacturer activity.
- Covered Entities that do not have an in-house pharmacy are able to designate a single contract pharmacy to continue to receive these medications at 340B price
- CaptureRx can help you identify the most appropriate contract pharmacy designee based on volume from the most relevant manufacturer(s)
- Verify that you are continuing to receive the 340B discount at your in-house pharmacy or designated contract pharmacy